Product Description: BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.
Applications: Cancer-Kinase/protease
Formula: C14H17N5
Citations: Aging (Albany NY). 2021 Aug 10;13(15):19088-19107./Am J Hematol. 2024 Apr 22./Am J Physiol Endocrinol Metab. 2021 Feb 15./Biochem Biophys Res Commun. 2023 Nov 5, 680, Pages 127-134./Biomed Pharmacother. 2020 Jul;127:110116./Cancer Metab. 2024 Jul 8;12(1):20./Front Microbiol. 2021 Feb 2;12:607451./Int Immunopharmacol. 2021 Oct 26;101(Pt A):108264./iScience. 2024 May 16./J Dent Res. 2019 Jul;98(8):896-903./J Pharmacol Sci. 2023 Dec, 153(4), 188-196./J Vet Sci. 2023 Sep 4;24(5):e72./J Virol. 2019 Nov 26;93(24):e01499-19./Nat Metab. 2023 Mar 6./PLoS Comput Biol. 2020 Jun 26;16(6):e1007901./Research Square Print. October 27th, 2022./Sci Transl Med. 2021 Jan 27;13(578):eaba7308./Cancer Cell. 2015 Mar 9;27(3):409-25. /Cell Res. 2019 Mar;29(3):193-205. /Cell Syst. 2018 Apr 25;6(4):424-443.e7./Harvard Medical School LINCS LIBRARY/J Mol Med. 2020 Oct;98(10):1479-1491.
References: [1]Burke JR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem, 2003, 278(3), 1450-1456./[2]Yang J, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res, 2006, 12(3 Pt 1), 950-960./[3]MacMaster JF, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res, 2003, 52(12), 508-511.
CAS Number: 445430-58-0
Molecular Weight: 255.32
Compound Purity: 99.86
Research Area: Cancer
Solubility: DMSO : 10 mg/mL (ultrasonic)/H2O : 10 mg/mL (ultrasonic;warming;heat to 60°C)
Target: IKK
Deutsch
English
